Jing Ai

USPTO Granted Patents = 11 (Patent Applications = 7)

CIPO Patents = 7 (Patent Applications = 2)

EPO Patents = 9 (Patent Applications = 17)

Average Co-Inventor Count = 7.4

ph-index = 1

Forward Citations = 8(Granted Patents)

Location History:

Guangdong, CN (2020)
Shanghai, CN (2015 - 2023)

Company Filing History:

10 out of 3,086

Chinese Academy of Sciences

patents

2 out of 9

Shanghai Haihe Pharmaceutical Co., Ltd.

patents

2 out of 13

Shanghai Fochon Pharmaceutical Co., Ltd.

where one patent can have more than one assignee

Years Active: 2015-2025

Loading Chart...

11 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12479850 - Compound having Axl and c-Met kinase inhibitory activity, preparation thereof and application thereof (2025-11-25),

2. 11834432 - Substituted amino six-membered nitric heterocyclic ring compound and preparation and use thereof (2023-12-05),

3. 11655239 - Fused ring pyrimidine amino compound and preparation method, pharmaceutical composition, and use thereof (2023-05-23),

4. 11494853 - Method for acquiring water leakage amount of leakage area in water distribution system (2022-11-08),

5. 10988456 - O-aminoheteroaryl alkynyl-containing compound, preparation method therefor, and use thereof (2021-04-27),

6. 10710996 - Pyrido-azaheterecydic compound and preparation method and use thereof (2020-07-14),

7. 10683278 - Substituted quinolone derivatives, or pharmaceutically acceptable salts or stereoisomers thereof, and pharmaceutical compositions and use thereof (2020-06-16),

8. 10562900 - Indazole compounds as FGFR kinase inhibitor, preparation and use thereof (2020-02-18),

9. 10058566 - Sulfated polygulonic acid polysaccharide or pharmaceutical salt thereof, preparation method therefor and use thereof (2018-08-28),

10. 9567342 - Certain protein kinase inhibitors (2017-02-14),

11. 9206166 - Certain protein kinase inhibitors (2015-12-08),

Title: The Contributions of Inventor Jing Ai

Introduction: Jing Ai is an emerging inventor based in China. Although he holds no patents to his name at this time, his work with notable organizations indicates his potential and dedication to the field of technology and innovation.

Latest Patents: Currently, Jing Ai has not acquired any patents, which suggests he may be in the early stages of his inventive career or focusing on research and development within established companies.

Career Highlights: Throughout his career, Jing Ai has gained valuable experience working with Shanghai Haihe Pharmaceutical Co., Ltd. and the Chinese Academy of Sciences. His roles in these organizations have provided him with insights into pharmaceutical innovations and scientific research methodologies.

Collaborations: Jing Ai's professional journey includes collaborations with esteemed colleagues such as Meiyu Geng and Lei Liu. These partnerships could potentially lead to future innovations and breakthroughs in their respective fields.

Conclusion: While Jing Ai may not yet have any patents to showcase, his contributions and collaborations within influential institutions reflect a promising trajectory in the field of innovation. With continued efforts and partnerships, it is likely that he will soon emerge as a recognized inventor in the industry.

This text is generated by artificial intelligence and may not be accurate.